Cancer risk

Bladder & kidney cancer

Dekalo S, McArthur E, Campbell J, Ordon M, Power N, Welk B. 5α-reductase inhibitors and the risk of bladder cancer in a large, population-based cohort. Urol Oncol. 2023. 10.1016/j.urolonc.2022.09.004PubMed

Doherty N, Cardwell CR, Murchie P, Hill C, Azoulay L, Hicks B. 5-alpha reductase inhibitors and risk of kidney and bladder cancers in men with benign prostatic hyperplasia: a population-based cohort study. Cancer Epidemiol Biomarkers Prev. 2023 Jan 12. doi:10.1158/1055-9965.EPI-22-1109 • PubMed

Garg H, Wheeler KM, Dursun F, et al. Impact of finasteride on survival in bladder cancer: a retrospective multi-institutional database analysis. Clin Genitourin Cancer. 2022. 10.1016/j.clgc.2022.10.014PubMed

Breast cancer

See also: Gynecomastia

Bird ST, Brophy JM, Hartzema AG, Delaney JA, Etminan M. Male breast cancer and 5α-reductase inhibitors finasteride and dutasteride. J Urol. 2013. doi:10.1016/j.juro.2013.04.132 • PubMed

Delfino M, Motola D, Mazzucchelli PP, Barotto M, Benini A, Campi A. Finastride e carcinoma mammario nell’uomo. Prima segnalazione di sospetta ADR in Italia [Finasteride and male breast cancer. First report of suspected ADR in Italy]. GIFAC. 2012. Italian. doi:10.1721/1109.12204

Duijnhoven RG, Straus SM, Souverein PC, et al. Long-term use of 5α-reductase inhibitors and the risk of male breast cancer. Cancer Causes Control. 2014. doi:10.1007/s10552-014-0455-6 • PubMed

Fang Q, Chen P, Du N, Nandakumar KS. Analysis of data from breast diseases treated with 5-alpha reductase inhibitors for benign prostatic hyperplasia. Clin Breast Cancer. 2019. 10.1016/j.clbc.2019.04.006 • PubMed

Green L, Wysowski DK, Fourcroy JL. Gynecomastia and breast cancer during finasteride therapy. N Engl J Med. 1996. doi:10.1056/NEJM199609123351116PubMed

Hagberg KW, Divan HA, Fang SC, Nickel JC, Jick SS. Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia. Clin Epidemiol. 2017. doi:10.2147/CLEP.S124674 • PubMed

Kjærulff TM, Ersbøll AK, Green A, et al. Finasteride use and risk of male breast cancer: a case-control study using individual-level registry data from Denmark, Finland, and Sweden. Cancer Epidemiol Biomarkers Prev. 2019. doi:10.1158/1055-9965.EPI-18-0904PubMed

Lee SC, Ellis RJ. Male breast cancer during finasteride therapy. J Natl Cancer Inst. 2004. doi:10.1093/jnci/djh062 • PubMed

Meijer M, Thygesen LC, Green A, et al. Finasteride treatment and male breast cancer: a register-based cohort study in four Nordic countries. Cancer Med. 2018. doi:10.1002/cam4.1273PubMed • PMC full text

Shenoy NK, Prabhakar SM. Finasteride and male breast cancer: Does the MHRA report show a link? J Cutan Aesthet Surg. 2010. doi:10.4103/0974-2077.69022 • Journal sitePubMedPMC full text

Esophageal & gastric cancer

Rabbani S, Santoni G, Lagergren J, Xie SH. Use of anti-androgenic 5α-reductase inhibitors and risk of oesophageal and gastric cancer by histological type and anatomical sub-site. Br J Cancer. 2022. doi:10.1038/s41416-022-01872-wPubMed

Prostate cancer

Anitha B, Inamadar AC, Ragunatha S. Finasteride-its impact on sexual function and prostate cancer. J Cutan Aesthet Surg. 2009. doi:10.4103/0974-2077.53093

Björnebo L, Nordström T, Discacciati A, et al. Association of 5α-reductase inhibitors with prostate cancer mortality. JAMA Oncol. 2022. doi:10.1001/jamaoncol.2022.1501. Erratum in: JAMA Oncol. 2022 Jun 16. PubMed

Bonde Miranda T, Garmo H, Stattin P, Robinson D. 5α-reductase inhibitors and risk of prostate cancer death. J Urol. 2020. doi:10.1097/JU.0000000000001038PubMed

Lynn R, Krunic A. Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction?. Dermatol Ther. 2010. doi:10.1111/j.1529-8019.2010.01358.x • PubMed

Pitts WR Jr. Finasteride (Propecia) and the promotion of high-grade prostate cancer. Arch Dermatol. 2004. doi:10.1001/archderm.140.7.885-b • PubMed

Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003. doi:10.1056/NEJMoa030660PubMed

Traish AM, Mulgaonkar A, Giordano N. The dark side of 5α-reductase inhibitors’ therapy: sexual dysfunction, high Gleason grade prostate cancer and depression. Korean J Urol. 2014. doi:10.4111/kju.2014.55.6.367 • PubMed

Wang L, Lei Y, Gao Y, et al. Association of finasteride with prostate cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2020. doi:10.1097/MD.0000000000019486 • PubMedPMC full text